12:00 AM
May 15, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Visudyne verteporfin: Began Phase IIIb trial enrollment

QLT PhotoTherapeutics Inc. (TSE:QLT; QLTI), Vancouver, B.C.
Product: Visudyne verteporfin
Business: Ophthalmic
Therapeutic category: Cytotoxic
Target: Leaking retinal blood vessels
Description: Photodynamic...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >